Technologies
Virongy Biosciences develops cutting-edge technologies in virology and viral vectors to accelerate scientific discovery, clinical diagnostics, and disease treatment.
Virongy's Key Technologies

- Cortical actin represents a structural impediment for viral intracellular migration towards sites where viruses replicate and assemble.
- Viruses devise strategies to exploit various cellular regulatory mechanisms of actin dynamics in order to overcome the cortical actin barrier.
- Many viruses use endocytosis to penetrate the cortical actin meshwork. The endosomal entry of viruses also requires active actin polymerization to drive endosome scission from the plasma membrane.
- Infectin is designed to increase actin dynamics to facilitate viral penetration of the cortical actin barrier, thereby greatly facilitating productive viral infection.
- Infectin can enhance the numbers of productively infected cells by 5- to 20-fold.
- It can be used to drastically increase the viral infection rate to facilitate biochemical characterization of viral infection.
- Infectin can be used as a routine viral infection-enhancing reagent to increase productive viral vector transduction rates, particularly for common vectors such as lenti- and retroviral vectors.
Hybrid alpha-pseudoviruses are a newly developed pseudovirus platform for rapidly screening viral entry inhibitors. They consist of a virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Ha-CoV-2 represents a major technology advancement in the development of SARS-CoV-2 pseudoviruses, and serves as platforms for rapid and robust quantification of neutralizing antibodies, viral mutants, and antiviral drugs (Dabbagh et al., 2021; He et al., 2021).
- Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-psedoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirus-based vector for rapid (6 hours) and robust expression of reporter genes.
- Neutralization assays conducted with Ha-CoV-2 and the infectious SARS-CoV-2 showed a direct correlation (R2 = 0.87) validating that Ha-CoV-2 can serve as a surrogate of SARS-CoV-2 for neutralizing antibody quantification
The HIV Rev-dependent reporter cells licensed and commercialized by Virongy represent a major advancement in the development of HIV indicator cells (Wu et al., 2007). This new reporter system differs dramatically from the common LTR-based reporter cells, which rely solely on the HIV promoter, the long terminal repeat (LTR), to drive reporter expression.
- While responsive to an early HIV protein, Tat, the LTR is also responsive to cell culture conditions and stimulation by a variety of known and unknown factors, including cytokines, mitogens, HDAC inhibitors, lipopolysaccharide, certain anti-tumor drugs, and free viral proteins (Siekevitz et al., 1987; Sweet et al., 1995).
- In contrast to the LTR-based reporter cells, our Rev-dependent reporter cells use both LTR and the Rev/RRE interaction to regulate reporter gene expression. This strict requirement for Rev, a viral protein present only in infected cells, drastically improves the reporter specificity and sensitivity.
- This unparalleled sensitivity and specificity means that our Rev-dependent reporter cells are suitable for a broad range of applications, including screening broadly neutralizing antibodies and anti-HIV drugs, and studying HIV cell-cell transmission and host restriction and dependency factors.
- Derived from CD4 T-cells, our reporter cells express native levels of HIV receptors, and are natural HIV targets with broad susceptibility to X4, R5, primary HIV isolates, and certain SIV strains.
- With GFP, Luc, or GFP/Luc detection options, our Rev-dependent cells provide a versatile and flexible platform for HIV research.
Endo, M., Ohashi, K., and Mizuno, K. (2007). LIM kinase and slingshot are critical for neurite extension. J Biol Chem 282, 13692-13702.
Foletta, V.C., Moussi, N., Sarmiere, P.D., Bamburg, J.R., and Bernard, O. (2004). LIM kinase 1, a key regulator of actin dynamics, is widely expressed in embryonic and adult tissues. Exp Cell Res 294, 392-405.
Guo J, Wang W, Yu D, Wu Y. Spinoculation triggers dynamic actin and cofilin activity facilitating HIV-1 infection of transformed and resting CD4 T cells. J Virol. 2011; 85(19):9824-33. PubMed PMID: 21795326.
Liu, G., Xiang, Y., Guo, C., Pei, Y., Wang, Y., and Kitazato, K. (2014). Cofilin-1 is involved in regulation of actin reorganization during influenza A virus assembly and budding. Biochem Biophys Res Commun 453, 821-825.
Manetti, F. (2012). Recent Findings Confirm LIM Domain Kinases as Emerging Target Candidates for Cancer Therapy. Curr Cancer Drug Targets 12, 543-560.
Nishimura, Y., Yoshioka, K., Bernard, O., Bereczky, B., and Itoh, K. (2006). A role of LIM kinase 1/cofilin pathway in regulating endocytic trafficking of EGF receptor in human breast cancer cells. Histochem Cell Biol 126, 627-638.
Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC. Activation of the HIV-1 LTR by T cell mitogens and the transactivator protein of HTLV-I. Science. 1987; 238:1575–1578.
Sweet MJ, Hume DA. RAW264 macrophages stably transfected with an HIV-1 LTR reporter gene provide a sensitive bioassay for analysis of signalling pathways in macrophages stimulated with lipopolysaccharide, TNF-alpha or taxol. J Inflamm. 1995; 45:126 –135.
Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011; 477(7362):95-8. PubMed PMID: 21849975.
Spear M, Guo J, Turner A, Yu D, Wang W, Meltzer B, et al. HIV-1 triggers WAVE2 phosphorylation in primary CD4 T cells and macrophages, mediating Arp2/3-dependent nuclear migration. J Biol Chem. 2014; 289(10):6949-59. PubMed PMID: 24415754; PubMed Central PMCID: PMC3945356.
Sloan RD, Kuhl BD, Donahue DA, Roland A, Bar-Magen T, Wainberg MA. Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef. J Virol. 2011; 85(6):2828-36. PubMed PMID: 21209113.
Shuck-Lee D, Chang H, Sloan EA, Hammarskjold ML, Rekosh D. Single-nucleotide changes in the HIV Rev-response element mediate resistance to com-pounds that inhibit Rev function. J Virol. 2011; 85(8):3940-9. PubMed PMID: 21289114.
Vorster, P.J., Guo, J., Yoder, A., Wang, W., Zheng, Y., Xu, X., Yu, D., Spear, M., and Wu, Y. (2011). LIM kinase 1 modulates cortical actin and CXCR4 cycling and is activated by HIV-1 to initiate viral infection. J Biol Chem 286, 12554-12564.
Wu Y, Beddall MH, Marsh JW. Rev-dependent indicator T cell line. Current HIV Research. 2007; 5:395-403.
Yang, N., Higuchi, O., Ohashi, K., Nagata, K., Wada, A., Kangawa, K., Nishida, E., and Mizuno, K. (1998). Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 393, 809-812.
Yi, F., Guo, J., Dabbagh, D., Spear, M., He, S., Kehn-Hall, K., Fontenot, J., Yin, Y., Bibian, M., Park, C.M., et al. (2017). Discovery of Novel Small Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1. J Virol. 91:e02418-16.
Yoshioka, K., Foletta, V., Bernard, O., and Itoh, K. (2003). A role for LIM kinase in cancer invasion. Proc Natl Acad Sci U S A 100, 7247-7252.
Yu D, Wang W, Yoder A, Spear M, Wu Y. The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog. 2009; 5(10):e1000633. PubMed PMID: 19851458.
Yoder A, Yu D, Dong L, Iyer SR, Xu X, Kelly J, et al. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell. 2008; 134(5):782-92. PubMed PMID: 18775311.